Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia

O. Wiklund, S. O. Olofsson, G. Fager, G. Bondjers, B. Angelin, M. Erikson, Lars Berglund

Research output: Contribution to journalArticlepeer-review

168 Scopus citations


Serum concentrations of apolipoprotein(a) were measured in patients with heterozygous familial hypercholesterolaemia. The levels in 47 patients were a median of 2·5 times higher than those in controls matched for age and sex (240 [range 25-1245] vs 97 [7-1040] mg/l). Among patients with familial hypercholesterolaemia apo(a) levels were higher in those with (n=48) than in those without (n=72) ischaemic heart disease (283 [18-1245] vs 144 [7-741] mg/l); both in univariate and multivariate analysis serum apo(a) was the most significant variable distinguishing between the groups. Despite reducing LDL cholesterol by 30%, treatment with cholestyramine or pravastatin did not reduce apo(a) levels in these patients. These findings support the concept that apo(a) concentration is a genetic trait predisposing to ischaemic heart disease and imply that it may be useful in the identification of familial hypercholesterolaemia patients at high risk of coronary disease.

Original languageEnglish (US)
Pages (from-to)1360-1363
Number of pages4
JournalThe Lancet
Issue number8702
StatePublished - Jun 9 1990
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia'. Together they form a unique fingerprint.

Cite this